Development programme
SCALE — liraglutide 3.0 mg
The weight-management programme for liraglutide 3.0 mg, including trials in prediabetes, type 2 diabetes, obstructive sleep apnoea and adolescents.
The weight-management programme for liraglutide 3.0 mg, including trials in prediabetes, type 2 diabetes, obstructive sleep apnoea and adolescents.
Sponsor class: Manufacturer-sponsored. First record: 2011.
Showing 0 records on this page
Records in this programme
23 documents
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SCALE-OBESITY | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 3,731 | 2015 | High |
| SCALE-PREDIABETES | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 2,254 | 2017 | Moderate |
| SCALE-SLEEP-APNOEA | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 359 | 2016 | Moderate |
| SCALE-TEENS | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 251 | 2020 | Moderate |
| SCALE-OBESITY-BODY-COMPprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2015 | Very low |
| SCALE-OBESITY-ELDERLYprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2015 | Very low |
| SCALE-OBESITY-QOLprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2015 | Very low |
| SCALE-OBESITY-REGIONAL-CNprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2015 | Very low |
| SCALE-OBESITY-REGIONAL-JPprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2015 | Very low |
| SCALE-PREDIABETES-BIOMARKERprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| SCALE-PREDIABETES-DDIprogramme record | Liraglutide | Phase 1 | Reported | Randomised crossover | — | 2017 | Very low |
| SCALE-PREDIABETES-ELDERLYprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| SCALE-PREDIABETES-OLEprogramme record | Liraglutide | Phase 3 | Reported | Single-arm open-label | — | 2017 | Very low |
| SCALE-SLEEP-APNOEA-DDIprogramme record | Liraglutide | Phase 1 | Reported | Randomised crossover | — | 2016 | Very low |
| SCALE-SLEEP-APNOEA-HEPATIC-IMPprogramme record | Liraglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2016 | Very low |
| SCALE-SLEEP-APNOEA-PKprogramme record | Liraglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2016 | Very low |
| SCALE-SLEEP-APNOEA-REGIONAL-JPprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| SCALE-SLEEP-APNOEA-RENAL-IMPprogramme record | Liraglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2016 | Very low |
| SCALE-TEENS-BODY-COMPprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2020 | Very low |
| SCALE-TEENS-DDIprogramme record | Liraglutide | Phase 1 | Reported | Randomised crossover | — | 2020 | Very low |
| SCALE-TEENS-HEPATIC-IMPprogramme record | Liraglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2020 | Very low |
| SCALE-TEENS-PKprogramme record | Liraglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2020 | Very low |
| SCALE-TEENS-RENAL-IMPprogramme record | Liraglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2020 | Very low |